NCT03229278 - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

October 20, 2022

Study Completion Date

October 30, 2022

Conditions

LymphomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell CancerRecurrent Bladder CarcinomaRecurrent Classical Hodgkin LymphomaRecurrent Head and Neck Squamous Cell CarcinomaRecurrent LymphomaRecurrent Malignant Solid NeoplasmRecurrent Renal Cell CarcinomaStage III Bladder CancerStage III LymphomaStage III Non-Small Cell Lung Cancer AJCC v7Stage III Renal Cell CancerStage III Skin MelanomaStage IIIA Non-Small Cell Lung Cancer AJCC v7Stage IIIA Skin MelanomaStage IIIB Non-Small Cell Lung Cancer AJCC v7Stage IIIB Skin MelanomaStage IIIC Skin MelanomaStage IV Bladder CancerStage IV LymphomaStage IV Non-Small Cell Lung Cancer AJCC v7Stage IV Renal Cell CancerStage IV Skin MelanomaStage IVA Bladder CancerStage IVB Bladder CancerUnresectable Head and Neck Squamous Cell CarcinomaUnresectable Solid Neoplasm

Interventions

DRUG

Enzyme Inhibitor Therapy

Given trigriluzole PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Rutgers, The State University of New Jersey

OTHER